Zurück zu Ihrem Suchergebnis

Beschreibung

Cancer autoantibodies have been studied as reporters of early carcinogenesis and indicators of cancer prognosis. Autoantibodies to tumor-associated antigens are putative cancer biomarkers, as these autoantibodies are abundant, detectable in early stages, and stable in serum. These autoantibodies may be developed from humoral immune responses to the changes in the expression levels of tumor-associated self-antigens, misfolded proteins, mutant antigens, and proteins involved in inflammation and the cellular death process. While the frequency of cancer autoantibody responses to an individual tumor antigen is typically low, the response to a multiplexed panel of antigens could be much higher. An optimized multiplex autoantibody panel to common tumor-associated antigens can improve the potential of using autoantibodies as biomarkers to study cancer development and progression, and it can serve as a simple and affordable tool in evaluating large numbers of patient samples for multiple cancer types.The MILLIPLEX(R) MAP Human Cancer Autoantibody Magnetic Bead Panel is a 15-plex kit to be used for the simultaneous quantification of autoantibodies to any or all of the following analytes in serum and plasma samples: Alpha-enolase (ENO1), Cancer/Testis Antigen 1B (CTAG1B/NY-ESO-1), Cyclin-dependent kinase 4 inhibitor A (p16-INK4a), G2/mitotic-specific cyclin-B1 (CCNB1), Galactose-specific lectin-1 (Galectin 1), Galactose-specific lectin-3 (Galectin 3), Heat shock protein 60 (HSP60), Hypoxia-inducible factor 1-alpha (HIF1alpha), Insulin-like growth factor 2 mRNA-binding protein 2 (IMP-2), Insulin-like growth factor 2 mRNA-binding protein 3 (IMP-3), Mucin 1 (MUC1), Receptor tyrosine-protein kinase (HER2/ErbB2), sex determining region Y (SRY)-box 2 (SOX2), Survivin (Survivin/BIRC5), and Tumor protein p53 (p53). For this particular panel, four assay control beads are included as part of the base kit format.